WCM/EADO 2021 | Vismodegib in basal cell carcinoma
Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, describes a recent multicenter real-world evidence study on the use of vismodegib, a hedgehog pathway inhibitor, in treating advanced basal cell carcinoma (BCC). Retrospective analysis of data from 108 patients with locally advanced or metastatic BCC demonstrated that treatment with vismodegib resulted in a median progression free survival (PFS) rate of over 30 months, a two year PFS rate of over 60% and only 5% of patients reporting grade 3 and 4 adverse events. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Piotr Rutkowski, MD, PhD has received honoraria for lectures and Advisory Boards from MSD, BMS, Novartis, Pierre Fabre, Sanofi, Merck and Blueprint Medicines.
